Inferior vena cava filter

Global Inferior Vena Cava Filters (IVCF) Pipeline Research Report 2023: Stages of Development, Segments, Region, Regulatory Path and Key Companies - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023
Health, Pharmaceutical, Inferior vena cava filter, Clinical trial, IVCF, Development

The "Inferior Vena Cava Filters (IVCF) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inferior Vena Cava Filters (IVCF) Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies" report has been added to ResearchAndMarkets.com's offering.
  • This report offers an extensive overview of the development landscape of Inferior Vena Cava Filters (IVCF), covering several essential aspects.
  • Firstly, it provides comprehensive coverage of IVCF products currently under development, offering insights into the latest advancements and innovations in this field.
  • Lastly, the report highlights recent developments within the Inferior Vena Cava Filters (IVCF) segment and the broader industry, ensuring that readers are informed about the latest trends and advancements.

New study demonstrates inferior vena cava (IVC) filters are safe and effective way to treat venous thromboembolism (VTE)

Retrieved on: 
Thursday, February 23, 2023
Beth Israel Deaconess Medical Center, Death, Safety, Journal of Vascular and Interventional Radiology, DVT, Society, Interventional radiology, PE, Embolism, Physician, JVIR, Recurrence, Inferior vena cava filter, PES, Risk, Health, Society of Interventional Radiology, Filter, Deep vein thrombosis, SIR, Journal, FDA, Radiology, Patient, Indiana University School of Medicine, Effectiveness, VTE, IVC, SVS, Society for Vascular Surgery, Coronary thrombosis, MS, FACS, Inferior vena cava, Pulmonary embolism, Birth control, Medical imaging, Nursing, MD, DRS

CHICAGO and FAIRFAX, Va., Feb. 23, 2023 /PRNewswire/ -- Few adverse events are connected to the use of inferior vena cava (IVC) filters to help prevent deep vein blood clots from developing into pulmonary embolisms (PE), according to the findings of the Predicting the Safety and Effectiveness of Inferior Vena Cava Filters (PRESERVE) trial, published jointly in the Journal of Vascular and Interventional Radiology (JVIR) and the Journal of Vascular Surgery Venous and Lymphatics (JVSVL).

Key Points: 
  • PRESERVE is an FDA-directed multicenter, prospective, open-label, non-randomized trial that studied the safety and efficacy of IVC filters from six manufacturers.
  • The study was conducted at 54 sites in the United States between Oct. 10, 2015, and March 31, 2019.
  • During that time, filters were implanted in 1,421 patients, of which 1,019 patients had an existing deep vein thrombosis (DVT) or pulmonary embolism (PE).
  • Approximately half of the patients in the study had their filters removed within 3 months of placement without complication or recurrence of DVT or PE, according to study authors.

First patients ‘filter free’ after laser-assisted Inferior Vena Cava (IVC) filter removal with Philips CavaClear

Retrieved on: 
Thursday, April 21, 2022
Patient, Filter, Travel, American Heart, PHG, Groin, Workflow, Philips, Stanford University, FCCP, Stanford University Medical Center, Research, Health, MD, Northwestern Medicine, Inferior vena cava, Leg, Associate, Stanford University School of Medicine, FSVM, Interventional radiology, Communication, Safety, IVC, Solution, Feinberg School of Medicine, Division, NYSE, Inferior vena cava filter, Fracture, Thrombosis, American Heart Association, AEX, Physician, FDA, Risk, Printed circuit board, Medical device, Dentistry, Medical imaging, Radiology, Medicine

First use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter

Key Points: 
  • First use of Philips' breakthrough CavaClear solution to help patients with embedded IVC filters, including an athlete suffering from a 16-year old penetrating filter
    Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the first patients have been successfully treated for Inferior Vena Cava (IVC) filter removal using its IVC Filter Removal Laser Sheath CavaClear .
  • In December 2021, Philips CavaClear IVC Filter Removal Laser Sheath received FDA De Novo clearance , becoming the first and only FDA-cleared solution for advanced IVC filter removal.
  • Failure rates for IVC filter removal can be high and prior to CavaClear, limited options for removal existed if the filter became difficult to remove.
  • LaserAssisted Removal of Embedded Vena Cava Filters: A FirstInHuman Escalation Trial in 500 Patients Refractory to HighForce Retrieval.

Global Interventional Cardiology & Peripheral Vascular Devices Market (2021 to 2029) - Featuring Cook Medical, Cardinal Health and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 11, 2022
Health, Medical Devices, Cardiology, CAGR, World Health Organization, WHO, Death, Degenerative disease, Growth, Cardiology, Research, Cardiovascular disease, American Heart Association, Moyamoya disease, World, Hypertension, Health, Prevalence, Government, Inferior vena cava filter, Diabetes, Atherectomy, Inferior vena cava, Medical imaging

Interventional cardiology and peripheral vascular devices market is experiencing lucrative growth with a moderate CAGR owing to increase in prevalence of cardiovascular diseases.

Key Points: 
  • Interventional cardiology and peripheral vascular devices market is experiencing lucrative growth with a moderate CAGR owing to increase in prevalence of cardiovascular diseases.
  • Surging inclination towards minimally invasive procedures will propel the growth of interventional cardiology and peripheral vascular devices market in the near future.
  • Cardiovascular diseases are more prevalent in elderly population, thus rising geriatric population contributes major growth to the interventional cardiology and peripheral vascular devices market.
  • Evolving technological advancement for developing improved devices and favorable reimbursement policies are further projected for driving the growth of interventional cardiology and peripheral vascular devices market.

Global Inferior Vena Cava Filters (Cardiovascular) Market Report 2022: Device Sales Analysis and Forecasts, 2015-2021 & 2022-2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 16, 2022
Health, Cardiology, Inferior vena cava, SWOT, CMO, Market access, IVCF, VTE, Inferior vena cava filter, Region, Country, Forecast model, Review, DVT, Filter, Venae cavae, Investment, Strategic planning, Risk, COVID-19, Extremities, Stainless steel, IVC, Anticoagulant, Nickel titanium, Blood, Epidemiology, Heart, PE, Industry, Coffee, Dry cleaning, Retail, Marketing, Titanium

The "Inferior Vena Cava Filters (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inferior Vena Cava Filters (Cardiovascular) - Global Market Analysis and Forecast Model" report has been added to ResearchAndMarkets.com's offering.
  • Inferior Vena Cava Filters (Cardiovascular) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.
  • The model discusses in detail the impact of COVID-19 on Inferior Vena Cava Filters market for the year 2020 and beyond.
  • Track device sales in the global and country-specific Inferior Vena Cava Filters market from 2015-2030.

Philips receives FDA De Novo Clearance for IVC Filter Removal Laser Sheath - CavaClear - with Breakthrough Device Designation

Retrieved on: 
Wednesday, December 22, 2021
Physician, Venae cavae, Filter, Technology, AEX, NYSE, Patient, Groin, American Heart, Inferior vena cava, Efficiency, Leg, Workflow, Method, Safety, Senior, IVC, Fracture, Thrombosis, Health, Travel, Communication, Associate, Inferior vena cava filter, Research, Feinberg School of Medicine, PHG, FDA, Medical device, Medical imaging, Radiology, Medicine

Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the FDA has granted De Novo Clearance for Philips IVC Filter Removal Laser Sheath CavaClear to remove an IVC filter when previous methods of removal have failed.

Key Points: 
  • Amsterdam, the Netherlands Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology today announced the FDA has granted De Novo Clearance for Philips IVC Filter Removal Laser Sheath CavaClear to remove an IVC filter when previous methods of removal have failed.
  • CavaClear is the first and only FDA-cleared solution for advanced IVC filter removal.
  • Earlier in 2021, the FDA granted the device Breakthrough Device Designation .
  • Failure rates for IVC filter removal can be high and prior to CavaClear, limited options for removal existed if the filter became difficult to remove.

Global PTA Balloon Catheters and Vena Cava Filters Market Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 15, 2021
Medical Devices, Health, BD, PTA, Cook Group, Inferior vena cava filter, Inferior vena cava, Abbott, Cardinal Health, COVID-19, Boston Scientific

The "Global PTA Balloon Catheters and Vena Cava Filters Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global PTA Balloon Catheters and Vena Cava Filters Market" report has been added to ResearchAndMarkets.com's offering.
  • This report covers the impact of COVID-19 on the PTA balloon catheters and vena cava filters market, including a recent forecast from 2020 to 2025.
  • COVID-19 has also impacted leading competitors, such as Abbott, BD, Boston Scientific, Cook Medical, Cardinal Health, and others.
  • The report provides insights into trends, drivers, and limiters of this market, as well as highlights potential opportunities.

Global Vena Cava Filters Market (2021 to 2026) - Featuring ALN International, Argon Medical Devices and Medtronic Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 27, 2021
Medical Devices, Health, Thrombosis, DVT, Laboratory, Catheter, Incidence, Inferior vena cava, First Nations in Ontario, Coronavirus, Inferior vena cava filter, World Health Organization, Person, Cava, Death, World, Heart, Awareness, Lists of countries and territories, COVID-19, Patient, Degenerative disease, Pulmonary embolism, Recurrence, Venae cavae, United Nations, Embolism, Pharmaceutical industry

The vena cava filters are either permanently placed or are retrievable, depending on their use to prevent the recurrence of pulmonary embolism.

Key Points: 
  • The vena cava filters are either permanently placed or are retrievable, depending on their use to prevent the recurrence of pulmonary embolism.
  • The increasing incidence of such diseases will support the market growth of the vena cava filters market as more patients will require it for their treatment.
  • The vena cava filters treatment is a costly treatment which makes it unaffordable for a majority of patients.
  • The Covid-19 pandemic moderately impacted the global vena cava filters market as due to the nationwide lockdown restrictions; many patients deferred their ongoing treatments to avoid public places which hampered the market growth.

Worldwide Inferior Vena Cava Filters Industry to 2026 - Featuring Argon Medical, Cardinal Health and Cook Medical Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 25, 2021
Health, Medical Supplies, Medical Devices, IVCF, CAGR, Inferior vena cava filter, Review, Lists of people executed in the United States, SME, MM, Coffee, Dry cleaning

Their opinion helps to understand and validate current and emerging therapies treatment patterns or Inferior Vena Cava Filters (IVCF) market trend.

Key Points: 
  • Their opinion helps to understand and validate current and emerging therapies treatment patterns or Inferior Vena Cava Filters (IVCF) market trend.
  • Additionally, an all-inclusive account of the currently available Inferior Vena Cava Filters (IVCF) is provided, which will have an impact on the future market of Inferior Vena Cava Filters (IVCF).
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the Inferior Vena Cava Filters (IVCF) market.
  • The report helps in developing business strategies by understanding trends shaping and driving the Inferior Vena Cava Filters (IVCF) market.

Federal Jury in Dallas Finds Bard's IVC Blood Clot Filter Defective and Dangerous

Retrieved on: 
Friday, July 23, 2021
Inferior vena cava filter, Interventional radiology, Legal procedure, Bard, Verdict, Jury, European literature, Literature, Articles

Bard's IVC blood clot filter is defective and responsible for injuries and complications.

Key Points: 
  • Bard's IVC blood clot filter is defective and responsible for injuries and complications.
  • The latest verdict for trial lawyers at Dallas-based Martin Baughman brings combined monetary awards to more than $7 million.
  • In the Dallas case, jurors found that Bard's Recovery IVC filter caused serious medical complications when it fractured after being implanted.
  • "We are very happy the jury held Bard accountable for Bard's misdeeds," said Charla Aldous of Aldous\Walker, Dallas, Texas, who tried the case with Mr. Martin in Dallas.